Literature DB >> 30031913

Dose-dependent target diversion of Danhong injection on the Glu-GLT-1/Gly-GlyRα dynamic balance module of cerebral ischemia.

Wenjuan Xu1, Yingying Zhang2, Yanan Yu3, Bing Li4, Jun Liu3, Pengqian Wang5, Hongli Wu3, Qiong Liu3, Ziyi Wei1, Hongbin Xiao6, Zhong Wang7.   

Abstract

Function-oriented modular structure analysis is a great challenge in module-based pharmacological studies. A strategy to uncover target-target interaction (TTI) and dynamic balance regularity (DBR) was established to discover the structural factors influencing modular functions and explore the mechanism of Danhong injection (DHI) in treating cerebral ischemia. The dose-related metabolic features of DHI intervention were investigated using metabolomics and modular pharmacology. The findings indicated that Glu/Gly was a biomarker and Glu-GLT-1/Gly-GlyRα was the core unit regulated by DHI. Gly and Glu displayed opposite patterns and functional roles, representing intra-modular balance. GlyRα was identified as the upstream target and GLT-1 as the downstream target by inhibiting or activating GlyRα, indicating that DHI has two dose-dependent regulatory modes. GlyRα was the major target at low doses, while GLT-1 was activated as the dominant target as doses accumulated. Our study reveals that target-target interaction and dynamic balance regularity are the key factors influencing modular functions, which is a promising breakthrough for module-based pharmacological studies.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Cerebral ischemia; Dose-dependent regularity; Dynamic balance regularity; Metabolomics; Modular pharmacology; Target-target interaction

Mesh:

Substances:

Year:  2018        PMID: 30031913     DOI: 10.1016/j.phrs.2018.07.020

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Identification of potential plasma biomarkers and metabolic dysfunction for unstable angina pectoris and its complication based on global metabolomics.

Authors:  Juan Wang; Wenjuan Xu; Huihui Zhao; Jianxin Chen; Bin Zhu; Xueli Li; Dong Deng; Jinping Wang; Junjie Liu; Yingting Yu; Hongbin Xiao; Wei Wang
Journal:  Biosci Rep       Date:  2019-03-22       Impact factor: 3.840

2.  Dose-Dependent Variation of Synchronous Metabolites and Modules in a Yin/Yang Transformation Model of Appointed Ischemia Metabolic Networks.

Authors:  Yifei Qi; Niwen Zhou; Qing Jiang; Zhi Wang; Yingying Zhang; Bing Li; Wenjuan Xu; Jun Liu; Zhong Wang; Lixing Zhu
Journal:  Front Neurosci       Date:  2021-08-20       Impact factor: 4.677

3.  Integrated Metabolomics and Network Pharmacology Revealed Hong-Hua-Xiao-Yao Tablet's Effect of Mediating Hormone Synthesis in the Treatment of Mammary Gland Hyperplasia.

Authors:  Ziqing Gao; Rui Mi; Zhaoxi Cheng; Xiaofeng Li; Huawu Zeng; Gaosong Wu; Jing Zhao; Weidong Zhang; Ji Ye
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

4.  The add-on effects of Danhong injection among patients with ischemic stroke receiving Western medicines: A systematic review and meta-analysis.

Authors:  Yu Ma; Ke Deng; Jiali Liu; Bin Ma; Fan Mei; Wen Hui; Xiaochao Luo; Minghong Yao; Yanmei Liu; Xuan Qin; Xu Zhou; Kang Zou; Ling Li; Xin Sun
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

5.  Pharmacokinetics of Active Ingredients of Salvia miltiorrhiza and Carthamus tinctorius in Compatibility in Normal and Cerebral Ischemia Rats: A Comparative Study.

Authors:  Ying Jin; Li Yu; Fangfang Xu; Jie Zhou; Bing Xiong; Yinshan Tang; Xiaohong Li; Lanying Liu; Weifeng Jin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-04       Impact factor: 2.441

6.  The Ameliorative Effects of Arctiin and Arctigenin on the Oxidative Injury of Lung Induced by Silica via TLR-4/NLRP3/TGF-β Signaling Pathway.

Authors:  Xueying Liu; Jian Wang; Peiyuan Dou; Xu Zhang; Xiaoku Ran; Linlin Liu; Deqiang Dou
Journal:  Oxid Med Cell Longev       Date:  2021-07-17       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.